Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help ...

2. FDA decision upheld: Two federal judges have backed the FDA’s decision to declare shortages of Zepbound, Mounjaro, Ozempic and Wegovy as resolved.

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Pittman rejected a separate challenge in May brought by the same groups over the FDA's removal of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro from the shortage list.